Zu den Inhalten springen


Workgroups and Sections

Research activities at the Center for Diagnostic and Therapeutic Radiology of the Medical Center - University of Freiburg are distributed in sections and divisions as follows:

  • Clinical Studies Section
  • Radiation Biology Research Section
  • Medical Physics Division
  • Interventional Radiotherapy Section
  • Clinical and Administrative Informatics Division

Research Studies


App Controlled Feedback System for Head and Neck Cancer Patients during Radiation Therapy


Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: A prospective, randomized, multicenter phase II trial of the German Rectal Cancer Study Group (Sponsored by German Cancer Aid).


Radio biologic profiling for a biologic stratified radiochemotherapy of head and neck tumors: a multicenter retrospective study by DKTK (German Cancer Consortium for Translational Cancer Research).


Dose-intensified image-guided fractionated stereotactic body radiation therapy for painful spinal metastases (DOSIS) versus conventional radiation therapy: A phase II randomized controlled trial.


Perioperative chemotherapy (FLOT Protocol) compared to neoadjuvant chemoradiation (CROSS Protocol) in patients with adenocarcinoma of the esophagus: a prospective, randomized phase III study.


Evaluation of 18F-MISO-PET detectable changes in proliferation and dispersion of hypoxic subvolume in head and neck cancer in patients undergoing radio(chemo)therapy: a prospective phase II study.


Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme - a randomized multicenter phase II trial (sponsored by Deutsche Krebshilfe e.V. – German Cancer Aid).


A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)

Hipporad MC

Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging: a prospective, randomized, multicenter phase II study (sponsored by German Cancer Aid).


Influence of timing of Radiotherapy of Immune respoNse in patients with metastasized melanomA


Lung cancer, Ablative high Precision radiotherapy and the Immune System: Evaluation of the immune-modulatory effects of stereotactic body radiation therapy (SBRT) of pulmonary lesions.


Comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement: EORTC Protocol 22055-08053, a prospective, randomized, multicenter phase III study.


Stereotactic fractionated radiotherapy in patients with medically inoperable small lung tumors: a prospective phase II study (Sponsored by German Cancer Aid).

Bitte akzeptieren Sie Youtube um dieses Video anzuschauen.

Multiple Myeloma

Prospective assessment of quality-of-life in highly conformal radiation therapy in addition to guideline-based drug therapy in patients with bone involvement in multiple myeloma.


Investigating efficacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery: An open label randomized phase II clinical trial.


Comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized or locally advanced prostate cancer. A phase IIIb randomized trial (EORTC-1414-ROG-GUCG).


Postoperative radiotherapy of non-small cell lung cancer: Accelerated vs. conventional fractionation.


A phase I-trial of NovoTTF-100A prior and concomitant to radiotherapy and temozolomide in newly diagnosed glioblastoma


Radiochemotherapy +/- Durvalumab for Anal Carcinoma, a Prospective Randomized Phase II trial


RadImmun-NSCLC: Evaluation of systemic effects of combined palliative radio- and immunotherapy in patients with metastatic non-small cell lung cancer after insufficient response to Nivolumab therapy.


Association between the occurrence of mucositis, changes in salivary parameters and cellular wound healing power after radiotherapy in the head-neck area.


Better protection of normal organs close to lesions in stereotactic body radiotherapy (SIP CHAI - Simultaneous Integrated Protection of Challenging Indications of SBRT).


The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care - TIGER study


Target structures of individual radiation sensitivity.

Further Strategies and Goals

Our most important current research topics are:

  • Advancing and establishing high-precision radiotherapy
  • Imaging procedures in radiotherapy planning and in monitoring
  • Combination of radio-sensitizing and / or radio-protective substances with radiotherapy
  • Radiation biology
  • Palliative and supportive radiation oncology / quality of life
  • High precision radiation and imaging in therapeutic radiology

Radiation Biology

  • Investigating radiation induced cell death modes in tumor cells, especially in tumor stem cells
  • Testing potential radiosensitizers for tumor stem cells
  • Establishing antibody-based methods for the noninvasive in-vivo imaging of tumor stem cells
  • Developing combined radiation and immunotherapy methods with the goal of inducing an effective anti-tumor immunity

Research Fellowship

Clinician Scientist-Programm/IMM-PACT (Funding – German Research Foundation – DFG)

Dr. Alexander Rühle- Research Fellowship – Clinician Scientist-Programme – 1 January.2020 – 31 December.2022

Clinician Scientists/Berta-Ottenstein Programme

Dr. med. Constantinos Zamboglou – Research Fellowhip – Clinician Scientists/Berta-Ottenstein Programme - 1 July 2017 – 30 June 2020

PD Dr. med. Constantinos Zamboglou – Research Fellowship – Advanced Clinician Scientists / Berta-Ottenstein Programme – 1 January – 31 December 2021

Dr. med. Simon Spohn – Research Fellowship –Clinician Scientists / Berta-Ottenstein Programme – 1 January 2021 – 31 December 2023

Research Fellowhip - Else-Kröner-Fresenius

Dr. med. Ilinca Popp – Research Fellowhip - Else-Kröner-Fresenius- Immunological Causes and Therapy of Cancer – EXCEL-Programme (Excellent Clinician Scientist in Freiburg – Education for Leadership)- 1 August 2018 – 31 December 2020